These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19633474)

  • 41. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
    Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
    Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
    Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
    Zhang WQ; Li T; Li H
    Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
    Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
    PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
    Cortot AB
    Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials.
    Hotta K; Fujiwara Y; Kiura K; Takigawa N; Tabata M; Ueoka H; Tanimoto M
    J Thorac Oncol; 2007 May; 2(5):402-7. PubMed ID: 17473655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients.
    Arrieta O; Rios Trejo MA; Michel RM
    J Thorac Oncol; 2009 Aug; 4(8):1043. PubMed ID: 19633484
    [No Abstract]   [Full Text] [Related]  

  • 50. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 51. The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
    Higginson DS; Chen RC; Tracton G; Morris DE; Halle J; Rosenman JG; Stefanescu M; Pham E; Socinski MA; Marks LB
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e385-92. PubMed ID: 22857887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.
    Hotta K; Fujiwara Y; Matsuo K; Kiura K; Takigawa N; Tabata M; Tanimoto M
    J Thorac Oncol; 2009 Mar; 4(3):311-7. PubMed ID: 19190515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.
    Janku F; Berry DA; Gong J; Parsons HA; Stewart DJ; Kurzrock R
    Clin Cancer Res; 2012 Nov; 18(22):6356-63. PubMed ID: 23014530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
    Bergot E; Levallet G; Creveuil C; Lechapt E; Zalcman G
    Presse Med; 2011 Apr; 40(4 Pt 1):379-88. PubMed ID: 21376511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
    Thonnard AS; Bosquée L; Corhay JL
    Rev Med Liege; 2011 Mar; 66(3):121-5. PubMed ID: 21560426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated non-small cell lung cancer (NSCLC) patients.
    Cardona AF; Reguart N; Reveiz L
    J Thorac Oncol; 2009 Jan; 4(1):142-3. PubMed ID: 19096326
    [No Abstract]   [Full Text] [Related]  

  • 57. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 58. Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma.
    Nakashima K; Horita N; Nagai K; Manabe S; Murakami S; Ota E; Kaneko T
    J Thorac Oncol; 2016 Sep; 11(9):1574-85. PubMed ID: 27178983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer.
    Sekine I; Kubota K; Nishiwaki Y; Sasaki Y; Tamura T; Saijo N
    Ann Oncol; 1998 Oct; 9(10):1079-84. PubMed ID: 9834819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.
    Lourdes LS; Jalal SI; Hanna N
    Oncologist; 2015 Sep; 20(9):975-8. PubMed ID: 26268739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.